Table 1.
Cytotoxicity data of selected metallacycles against a panel of human cancer cells.
| Compound | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | References |
|---|---|---|---|---|---|
| 1 | 19.24 ± 7.13 μM (96 h)/SISO (0.24 ± 0.05/CDDP) | 3.12 ± 1.22 μM (96 h)/A-427 (1.27 ± 0.25/CDDP) | 9.47 ± 3.12 μM (96 h)/LCLC-103H (1.09 ± 0.40/CDDP) | 7.61 ± 6.65 μM (96 h)/5637 (0.37 ± 0.08/CDDP) | Microtitre assay (Terenzi et al., 2012) |
| 2a | 37.8 ± 3.3 μM (72 h)/U2OS (3.8 ± 3.0/CDDP) | >50 μM (72 h)/VM-1 (4.43 ± 0.05/CDDP) | 32.1 ± 7.4 μM (72 h)/MCF7 (6.7 ± 0.3/CDDP) | Domarco et al., 2017 | |
| 2b | 28.9 ± 4.1 μM (72 h)/U2OS (3.8 ± 3.0/CDDP) | 31.8 ± 0.5 μM (72 h)/VM-1 (4.43 ± 0.05/CDDP) | 39.4 ± 3.4 μM (72 h)/MCF7 (6.7 ± 0.3/CDDP) | Domarco et al., 2017 | |
| 2c | 42.3 ± 4.6 μM (72 h)/U2OS (3.8 ± 3.0/CDDP) | >50 μM (72 h)/VM-1 (4.43 ± 0.05/CDDP) | 39.6 ± 4.5 μM (72 h)/MCF7 (6.7 ± 0.3/CDDP) | Domarco et al., 2017 |